Beigene (ONC.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow - Longbridge

Quote List Quote List

Event Tracking

Dec8

UOB Securities Analysts Positive on BeiGene's Revenue Growth Potential

04:37

Dec7

Two Drugs of BeiGene Entered the Commercial Insurance Innovative Drugs Directory

03:19

Nov24

BeiGene's Q3 Total Revenue Reached 1.4 Billion USD, Up 41% YoY

06:33

Nov12

Beigene Reports Significant Q3 2025 Revenue Growth

09:59

Nov11

CMBI Raises Profit Forecast and Maintains Buy Rating for BeiGene

01:07

Nov10

BGBA's Brukinsa Surpasses Expectations, Leading in BTK Inhibitors Market

02:44

Schedules & Filings

Schedules

Filings

Nov6

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 1.412 B, Net Income 124.84 M, EPS 1.0399

Aug6

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 1.315 B, Net Income 94.32 M, EPS 0.78

May7

Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 1.117 B, Net Income 1.27 M, EPS 0.0114

View More

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change

View More